Renal Diseases Market Reports Empesis on Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease

The Frontier Pharma: Renal Diseases High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease assesses first-in-class innovation in the renal diseases pipeline, highlighting key trends and emerging treatment classes.

Pune, India - March 14, 2018 /MarketersMedia/ —

The renal diseases therapy area encompasses a range of diseases of the kidney, such as chronic kidney disease (CKD), acute kidney injury, diabetic nephropathy and focal segmental glomerulosclerosis. Renal diseases are becoming increasingly common due to the increased prevalence of hypertension and diabetes, two major causes of CKD. For most forms of renal diseases, early detection and management may slow down or prevent progression to renal failure and associated complications. However, many renal diseases are typically asymptomatic until they have progressed to end-stage renal disease (ESRD), which requires renal replacement therapies such as hemodialysis and renal transplantation, and is associated with substantial morbidity and mortality.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-renal-diseases-high-degree-of-innovation-and-diversity-with-products-targeting-immune-and-hormone-signaling-dominating-the-pipeline-for-chronic-kidney-disease

The first-in-class programs identified show considerable diversity, and the relatively high degree of innovation in the renal diseases therapy area makes for a promising development pipeline. It is clear that recent activity in this area has increased, partly owing to the growing recognition of the unmet medical need. Further investment in innovation would benefit the therapy area greatly, and likely prove a worthwhile investment, particularly for highly prevalent diseases such as CKD and diabetic nephropathy, for which there are a lack of effective pharmacotherapeutic options.

Get this report at: https://www.themarketreports.com/report/buy-now/935551

Scope
• With 365 products in active development, the pipeline is modestly sized. Does current pipeline innovation hold the potential to affect the future renal diseases market?
• There are 100 first-in-class products in the renal diseases pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
• The majority of first-in-class products were in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
• A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935551

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/renal-diseases-market-reports-empesis-on-targeting-immune-and-hormone-signaling-dominating-the-pipeline-for-chronic-kidney-disease/314328

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-renal-diseases-high-degree-of-innovation-and-diversity-with-products-targeting-immune-and-hormone-signaling-dominating-the-pipeline-for-chronic-kidney-disease%20%20

Source: MarketersMedia

Release ID: 314328

More Press Releases

Stocks struggle higher as markets remain volatile; oil drops

Dec 10, 2018

NEW YORK — U.S. stocks remained volatile Monday as the market took a dive in early trading only to erase those losses later and end slightly higher. The Dow Jones Industrial Average lost as much as 507 points in early trading before ending with a gain of 34. Energy companies fell as the price of crude oil dropped 3 percent, giving back its gains from last week. Banks fell as investors expected slower increases in interest rates. Technology companies led the gainers. Qualcomm rose after the chipmaker said a Chinese court banned some Apple phones as part of a long-running...

Markets Right Now: US stocks end a bumpy day slightly higher

Dec 10, 2018

NEW YORK — The latest on developments in financial markets (all times local): 4 p.m. Stocks ended another bumpy day slightly higher as gains by big technology companies helped the market erase an early plunge. Facebook added 3.2 percent and Microsoft rose 2.6 percent Monday. Chipmaker Qualcomm rose 2.2 percent after a Chinese court banned some Apple phones as part of a long-running dispute over patents. Energy companies fell as the price of crude oil dropped 3 percent, to give up its gains from last week. Exxon Mobil lost 1.4 percent. The S&P 500 rose 4 points, or 0.2 percent,...

Goodyear halts tire production in Venezuela as economy slips

Dec 10, 2018

VALENCIA, Venezuela — Goodyear Tire & Rubber Co. is halting production in Venezuela, making it the latest international corporation to abandon a South American nation in economic crisis, officials said Monday. Spokesman Eduardo Arguelles told The Associated Press that Goodyear-Venezuela had made the "difficult decision" to no longer produce tires in the country, which has seen an economic contraction worse than the U.S. Great Depression. "Our goal had been to maintain its operations, but economic conditions and U.S. sanctions have made this impossible," Arguelles said. The company had endured tens of millions in losses in recent years as the Venezuelan...

Markets Right Now: Stocks open sharply lower on Wall Street

Dec 10, 2018

NEW YORK — The latest on developments in financial markets (all times local): 9:35 a.m. Stocks are opening sharply lower as the arrest of a senior Chinese technology executive threatened to worsen trade tensions between China and the U.S. The price of oil also fell sharply early Thursday as OPEC leaders gathered to discuss possible cuts in production. The Dow Jones Industrial Average dropped as much as 500 points before erasing some of its losses. Boeing and Caterpillar, which would stand to lose much in an extended trade battle, fell the most in the Dow. Traders continued to shovel money...

Dow slides 700 points as US stocks veer sharply lower

Dec 10, 2018

U.S. stocks veered sharply lower in afternoon trading Tuesday, pulling the Dow Jones Industrial Average down 700 points. The wave of selling erased the market's gains from a day earlier, when stocks rallied on news that the U.S. and China had agreed to a temporary truce in their trade dispute. Investors' confidence in that truce appeared to falter Tuesday, contributing to renewed fears about a slowing global economy. Technology companies, banks and industrial stocks accounted for much of the sell-off as traders moved assets into the relative safety of U.S. government bonds, driving yields sharply lower. Utilities stocks rose. Smaller-company...

Subscribe to our newsletter!

Your Name

Your Email Address